OpenAI’s GPT-5.4 mini and nano models cut costs and latency while staying close to flagship performance, giving developers faster AI options for real-time apps without sacrificing core capabilities.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results